Docket No.

IN RE APPLICATION OF: Olivier DE LACHARRIERE, et al.

SERIAL NO: 09/686,997

FILED:

FOR:

USE OF DHEA OR PRECURSORS OR METABLOIC DERIVATIVES THEREOF AS A DEPOMINATION OF PATENTS IN, D.C. 20231

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Transmitted herewith is an amendment with marked up copy in the above-identified application.

- No additional fee is required
- Small entity status of this application under 37 C.F.R. §1.9 and §1.27 is claimed.
- Additional documents filed herewith:

The Fee has been calculated as shown below:

CLAIMS	CLAIMS REMAINING		HIGHEST NUMBER PREVIOUSLY PAID	NO. EXTRA CLAIMS	RATE	CALCULATIONS
TOTAL	35	MINUS	35	0	× \$18 =	\$0.00
INDEPENDENT	4	MINUS	4	0	× \$84 =	\$0.00
		□ MUL	TIPLE DEPENDENT	CLAIMS	+ \$280 =	\$0.00
			TOTAL OF A	BOVE CALCU	JLATIONS	\$0.00
		□ Reduction by 50% for filing by Small Entity				\$0.00
		□ Recor	dation of Assignment		+ \$40 =	\$0.00
					TOTAL	\$0.00

A check in the amount of

is attached.

- Please charge any additional Fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.
- If these papers are not considered timely filed by the Patent and Trademark Office, then a petition is hereby made under 37 C.F.R. §1.136, and any additional fees required under 37 C.F.R. §1.136 for any necessary extension of time may be charged to Deposit Account No. 15-0030. A duplicate copy of this sheet is enclosed.

OBLON, SPIVAK, McCLELLAND, MAIER-& NEUSTADT, P.C.

homes A. Poh L

Stephen G. Baxter, Ph.D.

Registration No. 32,884

Thomas A. Blinka, Ph.D. Registration No. 44,541

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 10/00)



NOV 0.2 2001

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

•

Olivier DE LACHARRIERE ET AL

: EXAMINER: WILLIS, M.

SERIAL NO.: 09/686,997

FILED: OCTOBER 12, 2000

: GROUP ART UNIT: 1619

FOR: USE OF DHEA OR PRECURSORS:

OR METABOLIC DERIVATIVES THEREOF AS A DEPIGMENTING

AGENT

AMENDMENT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

In response to the Official Action dated July 30, 2001, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks.

IN THE CLAIMS

Please amend the claims as follows:

4. (Amended) The method of Claim 1, wherein said metabolic derivative thereof is selected from the group consisting of 5-androstene 3β , 17β -diol, 5-androstene- 3β , 17β diol sulfate and 4-androstene-3, 17-dione.

Al